Effects of exenatide extended-release in patients with type 2 diabetes mellitus
Not Applicable
Completed
- Conditions
- type 2 diabetes mellitus
- Registration Number
- JPRN-UMIN000018740
- Lead Sponsor
- Tokyo Women's Medical University
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 100
Inclusion Criteria
Not provided
Exclusion Criteria
- patients contraindicated to the study drugs - patients treated with insulin - patients with uncontrollable hypertension - pregnant women or women who are possibly pregnant
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method The following outcomes are estimated 24 weeks after start of treatment: - Changes in blood pressure by ambulatory blood pressure monitoring - Changes in office blood pressure - Ratios of patients requiring changes in doses or contents of medications
- Secondary Outcome Measures
Name Time Method Changes in the following factors are estimated 24 weeks after start of treatment: - fasting blood sugar and HbA1c - inflammation: hsCRP - renal function: urinary protein/creatinine ratio, urinary albumin/creatinine ratio, and eGFR - renin-angiotensin system Blood: plasma renin activity, aldosterone, prorenin, and soluble (pro)renin receptor. Urine: prorenin, soluble (pro)renin receptor, and angiotensinogen - body weight, waist circumference, visceral fat area, and hANP - endothelial function: flow-mediated dilation - arterial stiffness: baPWV